Why it’s time to abandon the ICER

PharmacoEconomics

10 July 2020 - The incremental cost-effectiveness ratio (ICER) is the most commonly reported summary measure for economic evaluations of health technologies, however, considering ICERs is unnecessary. 

Alternative measures exist, based on the concept of ‘net benefit’.

Although previous authors have outlined advantages to using net benefit, many health technology assessment (HTA) agencies continue to use ICERs.

Read PharmacoEconomics Editorial

Michael Wonder

Posted by:

Michael Wonder